

FRANCESCO PAPALEO, Ph.D.

Curriculum Vitae

Date and Place of Birth:

Nationality:

Languages Spoken: Italian, French, English.

Office Address: Genetics of Cognition Laboratory (GeCo)

Neuroscience Area,

Istituto Italiano di Tecnologia,

Via Morego 30

16163 Genova, Italy

Phone: +39 0102896786

E-mail: francesco.papaleo@iit.it

Website: <https://geco.iit.it/>

Twitter: @LabPapaleo

EDUCATION / WORK EXPERIENCE

April 2019- present: Tenured Senior Researcher, Neuroscience Area, Istituto Italiano di Tecnologia, Genova, Italy.

January 2013- present: Adjunct Faculty Investigator, Lieber Institute for Brain Development. Baltimore, MD, USA.

February 2014- March 2019: Senior Researcher, Associate Professor level, Neuroscience and Brain Technologies Department, Istituto Italiano di Tecnologia, Genova, Italy.

December 2011- February 2014: Assistant Professor, Department of Pharmacological Sciences, University of Padova, Italy.

September 2010- February 2014: Tenure Track-1, Team Leader, Neuroscience and Brain Technologies Department, Istituto Italiano di Tecnologia, Genova, Italy.

September 2005- August 2010: Post Doctoral Fellow, Clinical Brain Disorders Branch, National Institute of Mental Health, NIH, Bethesda, USA. Supervisors: Dr. Daniel R. Weinberger and Dr. Jacqueline N. Crawley.

January 2005- August 2005: “Assistant Associé”, University of Bordeaux 2, France, Supervisors: Prof. Antoine Tabarin and Dr. Angelo Contarino.

July 2004- December 2004: Researcher, University of Bordeaux, France. Supervisors: Prof. Antoine Tabarin and Dr. Angelo Contarino.

September 2003- July 2004: Researcher, INSERM Unit 588, “Laboratoire de Physiopathologie du Comportement”, Bordeaux, France. Supervisors: Dr. Pier Vincenzo Piazza and Dr. Angelo Contarino.

January 2002- March 2005: PhD Student in Pharmacology and Toxicology, University of Padova, Italy. Supervisor: Dr. Angelo Contarino.

December 2000- November 2001: Pharmacist. S. Chiara pharmacy. Vicenza, Italy. Supervisor: Dr. Paolo Pretto.

October 1996- November 2001: Pharmacy graduate studies (110/110 *cum Laude*), University of Padova, Italy.

GRANTS

October 2020- October 2022: Principal Investigator. Research collaboration agreement with Friedrich Miescher Institute for Biomedical Research, Switzerland. Title: “Use of an innovative conditional D2-receptor knockout approach, coupled to time- and cell type-specific viral delivery to identify the critical targets in the mouse model LgDel”.

February 2020- January 2024: Principal Investigator. Fondazione Telethon – project GGP19103, title: “Improving developmental trajectories in 22q11.2 deletion syndrome by oxytocin: focus on anti-inflammatory effects”.

November 2018- March 2023: Principal Investigator. Ricerca Finalizzata Giovani Ricercatori 2016 - Ministero Salute – project GR-2016-02362413, title: “Dysbindin-antipsychotics psychopharmacogenetics: a mouse-human translational study towards personalized healthcare in bipolar disorders”.

July 2018- April 2021: Principal Investigator. Boehringer Ingelheim Pharma. Title: “Role of the frontocortical-parvalbumin system in higher-order cognitive functions and in the onset of cognitive deficits induced by schizophrenia-relevant mutations”.

September 2018- September 2020: Supervisor and hosting lab. Marie Skłodowska-Curie individual Fellowships to Celine Devroye. Grant N. 796244. SocialBrainCircuits.

October 2018: Principal Investigator. The MINDDS Action of the European COST Association (eCOST). Training school/hands-on workshop in “Convergence Neuroscience: bridging the gap between human patients and animal models of neurodevelopmental disorders”.

March 2016- December 2018: Principal Investigator. Compagnia di San Paolo grant n. 2015-0321. Title: “Utilizzo di variazioni genetiche in dysbindin-1 (dtnbp1) per lo sviluppo di trattamenti più efficaci e personalizzati per la schizofrenia”.

September 2015- March 2018: Principal Investigator. Brain & Behavior Research Foundation, 2015 NARSAD Independent Investigator grant n. 23234; Title: “Use of genetic-driven dysbindin-1 (DTNBP1) variations for more effective and personalized treatments in First Episode of Psychosis”.

January 2013- January 2017: Principal Investigator. Roche Postdoc Fellowship Program; title: “D2L/S-dysbindin genetic interaction: towards early detection and personalized interventions for cognitive deficits and schizophrenia”.

January 2014- December 2015: in charge of a work package. 2013 NARSAD Young Investigator grant. Title: “Indicated prevention with long-chain polyunsaturated omega-3 fatty acids in patients with 22q11 microdeletion syndrome genetically at high risk for psychosis: A randomised, double blind, placebo-controlled treatment trial”.

January 2013- May 2016: Principal Investigator. Ricerca Finalizzata Giovani Ricercatori 2010 - Ministero Salute – project GR-2010-2315883, title: “Schizophrenia pathogenetic mechanisms associated to dysbindin dysfunctions in fly and mouse models”.

September 2010- September 2014: Principal Investigator. Marie Curie FP7-Reintegration-Grants Call identifier: FP7-PEOPLE-2010-RG Grant n.268247 – SCHIZOGENES.

August 2008-August 2010: Principal Investigator. NIMH Julius Axelrod Memorial Fellowship Training Award. Behavioral characterization of genetically modified mice for schizophrenia-associated susceptibility genes.

AWARDS AND HONORS

October 2018: Scientific Director and Organizer of the Training school/hands-on workshop in “Convergence Neuroscience: bridging the gap between human patients and animal models of neurodevelopmental disorders”. Genova, Italy.

April 2018: Abilitazione Scientifica Nazionale, Full Professor, Fascia 1, Pharmacology.

December 2017: travel award, ACNP 56th Annual Meeting, USA.

July 2017: Scientific Director and Organizer of the International Summer School of Neuroscience. Noto, Italy.

March 2015: Spring 2015 JOVE/Med Associates Competition.

April 2014: the Marie Curie Alumni Association Travel Grant.

November 2012: Winter Conference on Brain Research Travel Fellowship Award.

May 2009: award as Preceptor, Howard Hughes Medical Institute Student Internship Program.

August 2008: NIMH Julius Axelrod Memorial Fellowship Training Award.

May 2008: award as Preceptor, Howard Hughes Medical Institute Student Internship Program.

May 2007: mentor to prize winner of the American Academy of Neurology (AAN) Neuroscience Research Prize; Boston, annual meeting of the AAN.

September 2005- August 2010: fellowship, National Institute of Mental Health, NIH, USA.

January 2002- December 2004: doctoral fellowship, pharmacology program, University of Padova, Italy.

October 2003: scholarship from the Italian Society of Pharmacology.

PROFESSIONAL SOCIETIES & SCIENTIFIC COMMITTEE

2018- : The Association for the Study of Animal Behaviour

2013- : Societa' Italiana di Farmacologia

2012- : Schizophrenia International Research Society

2012- : The Marie Curie Alumni Association

2008- : International Behavioral Neuroscience Society

2004- : Society for Neuroscience

2021- : Scientific Programme Committee, European College of Neuropsychopharmacology (ECNP).

2020- : Scientific Committee of the IIT IACUC (Institutional Animal Care and Use Committee), or OPBA (Organismo preposto al benessere degli animali).

PUBLICATIONS

1. Barcik W, Chiacchierini G, Bimpisidis Z, **Papaleo F***.
Immunology and microbiology: how do they affect social cognition and emotion recognition? **Current Opinion in Immunology**. 2021 May 28;71:46-54. doi: 10.1016/j.coi.2021.05.001. *Corresponding author.
2. Rogdaki M, Devroye C, Ciampoli M, Veronese M, Ashok AH, McCutcheon RA, Jauhar S, Bonoldi I, Gudbrandsen M, Daly E, van Amelsvoort T, Van Den Bree M, Owen MJ, Turkheimer F, **Papaleo F**, Howes OD.
Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study. **Molecular Psychiatry**. 2021 May 12. doi: 10.1038/s41380-021-01108-y.
3. Torrisi SA, Lavanco G, Maurel OM, Gulisano W, Laudani S, Geraci F, Grasso M, Barbagallo C, Caraci F, Bucolo C, Ragusa M, **Papaleo F**, Campolongo P, Puzzo D, Drago F, Salomone S, Leggio GM.
A novel arousal-based individual screening reveals susceptibility and resilience to PTSD-like phenotypes in mice. **Neurobiology of Stress**. 2020 Dec 24;14:100286. doi: 10.1016/j.ynstr.2020.100286. eCollection 2021 May.
4. Scarsi F, Scheggia D, **Papaleo F***.
Automated Two-Chamber Operon ID/ED Task for Mice. **Current Protocols in Neuroscience**. 2020 Dec;94(1):e109. doi: 10.1002/cpns.109. *Corresponding author.
5. Torrisi SA, Laudani S, Contarini G, De Luca A, Geraci F, Managò F, **Papaleo F**, Salomone S, Drago F, Leggio GM.
Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments. **Pharmaceuticals**. 2020 Nov 5;13(11):365. doi: 10.3390/ph13110365.
6. Maltese F, **Papaleo F***.
Oxytocin Discrepancies in Social Dynamics. **Neuron**. 2020 Aug 19;107(4):591-593. doi: 10.1016/j.neuron.2020.07.027. *Corresponding author.
7. Scheggia D, **Papaleo F***.
Social Neuroscience: Rats Can Be Considerate to Others. **Current Biology**. 2020 Mar 23;30(6):R274-R276. doi: 10.1016/j.cub.2020.01.093. *Corresponding author.
8. Romano GL, Platania CBM, Leggio GM, Torrisi SA, Giunta S, Salomone S, Purrello M, Ragusa M, Barbagallo C, Giblin FJ, Mastrogiacomo R, Managò F, Cammalleri M, **Papaleo F**, Drago F, Bucolo C.
Retinal biomarkers and pharmacological targets for Hermansky-Pudlak syndrome 7. **Scientific Reports**. 2020 Mar 4;10(1):3972. doi: 10.1038/s41598-020-60931-5.
9. Armando M, Ciampoli M, Padula MC, Amminger P, De Crescenzo F, Schneider M, Schaer M, Managò F, Eliez S, **Papaleo F***.
Favorable effects of omega-3 polyunsaturated fatty acids in attentional control and conversion rate to psychosis in 22q11.2 deletion syndrome. **Neuropharmacology**. 2020 May 15;168:107995. doi: 10.1016/j.neuropharm.2020.107995. *Corresponding author.

10. Pagani M, De Felice A, Montani C, Galbusera A, **Papaleo F**, Gozzi A. Acute and Repeated Intranasal Oxytocin Differentially Modulate Brain-wide Functional Connectivity. **Neuroscience**. 2020 Jan 7. doi: 10.1016/j.neuroscience.2019.12.036.
11. Scheggia D, Managò F, Maltese F, Bruni S, Nigro M, Dautan D, Latuske P, Contarini G, Gomez-Gonzalo M, Reque LM, Ferretti V, Castellani G, Mauro D, Bonavia A, Carmignoto G, Yizhar O, **Papaleo F***. Somatostatin interneurons in the prefrontal cortex control affective state discrimination in mice. **Nature Neuroscience**. 2020 Jan;23(1):47-60. doi: 10.1038/s41593-019-0551-8. Epub 2019 Dec 16. ***Corresponding author**.
12. Espinoza S, Scarpato M, Damiani D, Managò F, Mereu M, Contestabile A, Peruzzo O, Carninci P, Santoro C, **Papaleo F**, Mingozzi F, Ronzitti G, Zucchelli S, Gustincich S. SINEUP Non-coding RNA Targeting GDNF Rescues Motor Deficits and Neurodegeneration in a Mouse Model of Parkinson's Disease. **Molecular Therapy**. 2019 Aug 16. doi: 10.1016/j.ymthe.2019.08.005.
13. Leggio GM, Torrisi SA, Mastrogiacomo R, Mauro D, Chisari M, Devroye C, Scheggia D, Nigro M, Geraci F, Pintori N, Giurdanella G, Costa L, Bucolo C, Ferretti V, Sortino MA, Ciranna L, De Luca MA, Mereu M, Managò F, Salomone S, Drago F, **Papaleo F***. The epistatic interaction between the dopamine D3 receptor and dysbindin-1 modulates higher-order cognitive functions in mice and humans. **Molecular Psychiatry**. 2019 Sep 6. doi: 10.1038/s41380-019-0511-4. ***Corresponding author**.
14. Gorinski N, Bijata M, Prasad S, Wirth A, Abdel Galil D, Zeug A, Bazovkina D, Kondaurova E, Kulikova E, Ilchibaeva T, Zareba-Koziol M, **Papaleo F**, Scheggia D, Kochlamazashvili G, Dityatev A, Smyth I, Krzystyniak A, Włodarczyk J, Richter DW, Strekalova T, Sigrist S, Bang C, Hobuß L, Fiedler J, Thum T, Naumenko VS, Pandey G, Ponimaskin E. Attenuated palmitoylation of serotonin receptor 5-HT1A affects receptor function and contributes to depression-like behaviors. **Nature Communications**. 2019 Sep 2;10(1):3924. doi: 10.1038/s41467-019-11876-5.
15. Contarini G, Ferretti V, **Papaleo F***. Acute Administration of URB597 Fatty Acid Amide Hydrolase Inhibitor Prevents Attentional Impairments by Distractors in Adolescent Mice. **Frontiers in Pharmacology**. 2019 Jul 19;10:787. doi: 10.3389/fphar.2019.00787. ***Corresponding author**.
16. Ferretti V, Maltese F, Contarini G, Nigro M, Bonavia A, Huang H, Morelli G, Scheggia D, Managò F, Castellani G, Cancedda L, Chini B, Grinevich V, **Papaleo F***. Oxytocin Signaling in the Central Amygdala Modulates Emotion Discrimination in Mice. **Current Biology**. 2019. 29, 1–16 June 17, doi.org/10.1016/j.cub.2019.04.070. ***Corresponding author**.
17. Castellani G, Contarini G, Mereu M, Albanesi E, Devroye C, D'Amore C, Ferretti V, De Martin S, **Papaleo F***. Dopamine-Mediated Immunomodulation affects Choroid Plexus Function. **Brain, Behavior, and Immunity**. 2019 June 5. ***Corresponding author**.
18. Morè L, Lauterborn JC, **Papaleo F***, Brambilla R.

Enhancing cognition through pharmacological and environmental interventions: examples from preclinical models of neurodevelopmental disorders. **Neuroscience & Biobehavioral Reviews**. 2019 Apr 10. doi: 10.1016/j.neubiorev.2019.02.003. Review. *Corresponding author.

19. Ferretti V, **Papaleo F***.

Understanding others: emotion recognition abilities in humans and other animals. **Genes, Brain Behavior**. 2018. Dec13:e12544. doi:10.1111/gbb.12544. *Corresponding author.

20. Szczurkowska J, Pischedda F, Pinto B, Managò F, Haas CA, Summa M, Bertorelli R, **Papaleo F**, Schäfer MK, Piccoli G, Cancedda L.

NEGR1 and FGFR2 cooperatively regulate cortical development and core behaviours related to autism disorders in mice. **Brain**. 2018 Jul 27. doi: 10.1093/brain/awy190.

21. Scheggia D, Mastrogiacomo R, Mereu M, Sannino S, Straub RE, Armando M, Managò F, Guadagna S, Piras F, Zhang F, Kleinman JE, Hyde TM, Kaalund SS, Pontillo M, Orso G, Caltagirone C, Borrelli E, De Luca MA, Vicari S, Weinberger DR, Spalletta G, **Papaleo F***.

Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment. **Nature Communications**. 2018 Jun 11;9(1):2265. doi:10.1038/s41467-018-04711-w. *Corresponding author.

22. Trusel M, Baldryghi M, Marotta R, Gatto F, Pesce M, Frasconi M, Catelani T, **Papaleo F**, Pompa PP, Tonini R, Giordani S.

Internalization of Carbon Nano-onions by Hippocampal Cells Preserves Neuronal Circuit Function and Recognition Memory. **ACS Appl Mater Interfaces**. 2018 May 23;10(20):16952-16963. doi:10.1021/acsami.7b17827. Epub 2018 May 9.

23. Carr GV, Maltese F, Sibley DR, Weinberger DR, **Papaleo F***.

The Dopamine D5 Receptor Is Involved in Working Memory. **Frontiers in Pharmacology**. 2017. Oct 6;8:666. doi: 10.3389/fphar.2017.00666. *Corresponding author.

24. Amato D, Vernon AC, **Papaleo F**.

Dopamine, the antipsychotic molecule: a perspective on mechanisms underlying antipsychotic response variability. **Neuroscience & Biobehavioral Reviews**. 2018 Feb;85:146-159. doi: 10.1016/j.neubiorev.2017.09.027. Epub 2017 Sep 29.

25. Managò F & **Papaleo F***.

Schizophrenia: What's Arc Got to Do with It? **Frontiers in Behavioral Neuroscience**. 2017. Sep 20; 11:181. doi: 10.3389/fnbeh.2017.00181. *Corresponding author.

26. Ciampoli M, Contarini G, Mereu M, **Papaleo F***.

Attentional Control in Adolescent Mice Assessed with a Modified Five Choice Serial Reaction Time Task. **Scientific Reports**. 2017 Aug 30;7(1):9936. doi: 10.1038/s41598-017-10112-8. *Corresponding author.

27. Scheggia D, Zamberletti E, Realini N, Mereu M, Contarini G, Ferretti V, Managò F, Margiani G, Brunoro R, Rubino T, De Luca MA, Piomelli D, Parolaro D, **Papaleo F***.

Remote memories are enhanced by COMT activity through dysregulation of the endocannabinoid system in the prefrontal cortex. **Molecular Psychiatry**. 2018

Apr;23(4):1040-1050. doi:10.1038/mp.2017.126. Epub 2017 Jun20. ***Corresponding author.**

28. Sannino S, Padula MC, Managò F, Schaer M, Schneider M, Armando M, Scariati E, Sloan-Bena F, Mereu M, Pontillo M, Vicari S, Contarini G, Chiabrera C, Pagani M, Gozzi A, Eliez S, **Papaleo F***.

Adolescence is the starting point of sex-dichotomous COMT genetic effects. **Transl Psychiatry.** 2017 May 30;7(5):e1141. doi: 10.1038/tp.2017.109. ***Corresponding author.**

29. Mereu M, Contarini G, Buonaguro EF, Latte G, Managò F, Iasevoli F, de Bartolomeis A, **Papaleo F***.

Dopamine transporter (DAT) genetic hypofunction in mice produces alterations consistent with ADHD but not schizophrenia or bipolar disorder. **Neuropharmacology.** 2017 Jul 15;121:179-194. doi:10.1016/j.neuropharm.2017.04.037. Epub 2017 Apr 26. ***Corresponding author.**

30. Huang H, Guadagna S, Mereu M, Ciampoli M, Pruzzo G, Ballard T, **Papaleo F***.

A schizophrenia relevant 5-Choice Serial Reaction Time Task for mice assessing broad monitoring, distractibility and impulsivity. **Psychopharmacology (Berl).** 2017 Jul;234(13):2047-2062. doi:10.1007/s00213-017-4611-z. Epub 2017 Apr 5. ***Corresponding author.**

31. Contarino A, Kitchener P, Vallée M, **Papaleo F**, Piazza PV.

CRF1 receptor-deficiency increases cocaine reward. **Neuropharmacology.** 2017 May 1;117:41-48. doi: 10.1016/j.neuropharm.2017.01.024. Epub 2017 Jan 27.

32. Galbusera A, De Felice A, Stefano G, Bassetto G, Maschietto M, Nishimori K, Chini B, **Papaleo F**, Vassanelli S, Gozzi A.

Intranasal Oxytocin and Vasopressin Modulate Divergent Brainwide Functional Substrates. **Neuropsychopharmacology.** 2017 Jun;42(7):1420-1434. doi: 10.1038/npp.2016.283. Epub 2016 Dec 20.

33. Managò F, Mereu M, Mastwal S, Mastrogiacomo R, Scheggia D, Emanuele M, De Luca MA, Weinberger DR, Wang KH, **Papaleo F***.

Genetic Disruption of Arc/Arg3.1 in Mice Causes Alterations in Dopamine and Neurobehavioral Phenotypes Related to Schizophrenia. **Cell Reports.** 2016 Aug 23;16(8):2116-28. doi: 10.1016/j.celrep.2016.07.044. ***Corresponding author.**

34. Carr GV, Chen J, Yang F, Ren M, Yuan P, Tian Q, Bebensee A, Zhang GY, Du J, Glineburg P, Xun R, Akhile O, Akuma D, Pickel J, Barrow JC, **Papaleo F**, Weinberger DR.

KCNH2-3.1 expression impairs cognition and alters neuronal function in a model of molecular pathology associated with schizophrenia. **Molecular Psychiatry.** 2016 Nov;21(11):1517-1526. doi: 10.1038/mp.2015.219.

35. **Papaleo F**, Yang F, Paterson C, Palumbo S, Carr GV, Wang Y, Floyd K, Huang W, Thomas CJ, Chen J, Weinberger DR, Law AJ.

Behavioral, Neurophysiological, and Synaptic Impairment in a Transgenic Neuregulin1 (NRG1-IV) Murine Schizophrenia Model. **J Neurosci.** 2016 Apr 27;36(17):4859-75. doi: 10.1523/JNEUROSCI.4632-15.2016.

36. Scheggia D, **Papaleo F***.

An Operant Intra-/Extra-dimensional Set-shift Task for Mice. **J Vis Exp.** 2016 Jan 22;(107). doi: 10.3791/53503. *Corresponding author.

37. Huang H, **Papaleo F***.

Genetic modulation of oxytocin's effects in social functioning. **Ann Transl Med.** 2015 Dec;3(22):348. doi: 10.3978/j.issn.2305-5839.2015.09.36. *Corresponding author.

38. **Papaleo F***, Sannino S, Piras F, Spalletta G.

Sex-dichotomous effects of functional COMT genetic variations on cognitive functions disappear after menopause in both health and schizophrenia. **Eur Neuropsychopharmacol.** 2015 Dec;25(12):2349-63. doi: 10.1016/j.euroneuro.2015.10.005. *Corresponding author.

39. Armando M, De Crescenzo F, Vicari S, Digilio MC, Pontillo M, **Papaleo F**, Amminger GP.

Indicated prevention with long-chain polyunsaturated omega-3 fatty acids in patients with 22q11DS genetically at high risk for psychosis. Protocol of a randomized, double-blind, placebo-controlled treatment trial. **Early Interv Psychiatry.** 2016 Oct;10(5):390-6. doi: 10.1111/eip.12197. Epub 2014 Oct 24.

40. Moran PM, O'Tuathaigh CM, **Papaleo F**, Waddington JL.

Dopaminergic function in relation to genes associated with risk for schizophrenia: translational mutant mouse models. **Prog Brain Res.** 2014; 211:79-112. doi: 10.1016/B978-0-444-63425-2.00004-0.

41. Sannino S, Gozzi A, Cerasa A, Piras F, Scheggia D, Manago F, Damiano M, Galbusera A, Erickson LC, Tonelli DDT, Bifone A, Tsafaris SA, Caltagirone C, Weinberger DR, Spalletta G, **Papaleo F***.

COMT Genetic Reduction Produces Sexually Divergent Effects on Cortical Anatomy and Working Memory in Mice and Humans. **Cerebral Cortex** 2015; Sep;25(9):2529-41. doi: 10.1093/cercor/bhu053. Epub 2014 Mar 21. *Corresponding author.

42. Huang H, Michetti C, Busnelli M, Managò F, Sannino S, Scheggia D, Giancardo L, Sona D, Murino V, Chini B, Luisa Scattoni M, **Papaleo F***.

Chronic and Acute Intranasal Oxytocin Produce Divergent Social Effects in Mice. **Neuropsychopharmacology.** 2014 Apr;39(5):1102-14. doi: 10.1038/npp.2013.310. Epub 2013 Nov 4. *Corresponding author.

43. **Papaleo F***, Burdick MC, Callicott JH, Weinberger DR.

Epistatic interaction between COMT and DTNBP1 modulates prefrontal function in mice and in humans. **Molecular Psychiatry.** 2014 Mar;19(3):311-6. doi: 10.1038/mp.2013.133. Epub 2013 Oct 22. *Corresponding author.

44. Giancardo L, Sona D, Huang H, Sannino S, Managò F, Scheggia D, **Papaleo F***, Murino V.

Automatic visual tracking and social behaviour analysis with multiple mice. **PLoS One.** 2013 Sep 16;8(9):e74557. doi: 10.1371/journal.pone.0074557. ***Corresponding author.**

45. Scheggia D, Bebensee A, Weinberger DR, **Papaleo F***. The Ultimate Intra/Extradimensional Attentional Set-Shifting Task for Mice. **Biol Psychiatry.** 2014 Apr 15;75(8):660-70. doi: 10.1016/j.biopsych.2013.05.021. Epub 2013 Jun 28. ***Corresponding author.**

46. Carr GV, Jenkins KA, Weinberger DR, **Papaleo F***. Loss of dysbindin-1 in mice impairs reward-based operant learning by increasing impulsive and compulsive behavior. **Behav Brain Res.** 2013 Mar 15;241:173-84. doi: 10.1016/j.bbr.2012.12.021. Epub 2012 Dec 20. ***Corresponding author.**

47. **Papaleo F***, Erickson L, Liu G, Chen J, Weinberger DR. Effects of sex and COMT genotype on environmentally modulated cognitive control in mice. **PNAS.** 2012 Dec 4;109(49):20160-5. doi: 10.1073/pnas.1214397109. Epub 2012 Nov 19. ***Corresponding author.**

48. Armando M, SabaR, MonducciE, **Papaleo F**, Dario C, RighettiV, BrandizziM, FioriP. Subtypes of psychotic-like experiences in a community sample of young adults: socio-demographic correlates and substance use. **Rivista di Psichiatria,** 2012, 47, 5: 424-431.

49. Law AJ, Wang Y, Sei Y, O'Donnell P, Piantadosi P, **Papaleo F**, Straub RE, Huang W, Thomas CJ, Vakkalanka R, Besterman AD, Lipska BK, Hyde TM, Harrison PJ, Kleinman JE, Weinberger DR. Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110 δ inhibition as a potential therapeutic strategy. **PNAS.** 2012 Jul 24;109(30):12165-70. doi: 10.1073/pnas.1206118109. Epub 2012 Jun 11.

50. Scheggia D, Sannino S, Scattoni ML, **Papaleo F***. COMT as a drug target for cognitive functions and dysfunctions. **CNS & Neurological Disorders-Drug Targets.** 2012 May;11(3):209-21. Review. ***Corresponding author.**

51. Armando M, **Papaleo F**, Vicari S. COMT implication in cognitive and psychiatric symptoms in chromosome 22q11 microdeletion syndrome. **CNS & Neurological Disorders-Drug Targets.** 2012 May;11(3):273-81. Review.

52. **Papaleo F***. COMT as a Drug Target for Nervous System Disorders. **CNS & Neurological Disorders-Drug Targets.** 2012 May;11(3):193-4. ***Corresponding author.**

53. Ingallinesi M, Rouibi K, Le Moine C, **Papaleo F**, Contarino A. CRF₂ receptor-deficiency eliminates opiate withdrawal distress without impairing stress-coping. **Molecular Psychiatry.** 2012 Dec;17(12):1283-94. doi: 10.1038/mp.2011.119. Epub 2011 Sep 27.

54. **Papaleo F***, Yang F, Garcia S, Chen J, Lu B, Crawley JN, Weinberger DR. Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways. **Molecular Psychiatry** 2012 Jan; 17(1):85-98. doi: 10.1038/mp.2010.106. Epub 2010 Oct 19. ***Corresponding author.**
55. **Papaleo F***, Silverman JL, Aney J, Tian Q, Barkan CL, Chadman KK, Crawley JN. Working memory deficits, increased anxiety-like traits and seizure susceptibility in BDNF overexpressing mice. **Learning & Memory**. 2011 Jul 26;18(8):534-44. Print 2011 Aug. ***Corresponding author.**
56. **Papaleo F***, Lipska BK, Weinberger DR. Mouse models of genetic effects on cognition: Relevance to schizophrenia. **Neuropharmacology**. 2012 Mar;62(3):1204-20. Epub 2011 May 5. ***Corresponding author.**
57. **Papaleo F**, Weinberger DR. Dysbindin and Schizophrenia: It's dopamine and glutamate all over again. **Biological Psychiatry**. 2011 January 1; 69(1): 2-4.
58. Ji Y, Yang F, **Papaleo F**, Wang HX, Gao WJ, Weinberger DR, Lu B. Role of dysbindin in dopamine receptor trafficking and cortical GABA function. **PNAS**. 2009 Nov 17; 106(46):19593-19598. Epub 2009 Nov 3.
59. **Papaleo F**, Crawley JN, Song J, Lipska BK, Pickel J, Weinberger DR, Chen J. Genetic dissection of the role of Catechol-O-Methyltransferase in cognition and stress reactivity in mice. **J. Neurosci**. 2008 Aug 27; 28(35):8709-23. doi: 10.1523/JNEUROSCI.2077-08.2008.
60. **Papaleo F**, Ghazizadeh S, Ingallinesi M, Roberts AJ, Koob GF, Contarino A. Disruption of the CRF₂ receptor pathway decreases the somatic expression of opiate withdrawal. **Neuropsychopharmacology**. 2008 Nov;33(12):2878-87. Epub 2008 Feb 20.
61. **Papaleo F**, Kieffer BL, Tabarin A, Contarino A. Decreased motivation to eat in μ -opioid receptor-deficient mice. **European Journal of Neuroscience**. 2007 Jun; 25(11):3398-3405.
62. **Papaleo F**, Kitchener P, Contarino A. Disruption of the CRF/CRF₁ receptor stress system exacerbates the somatic signs of opiate withdrawal. **Neuron**. 2007 Feb 15;53(4):577-589.
63. **Papaleo F** and Contarino A. Gender- and morphine dose-linked expression of spontaneous somatic opiate withdrawal in mice. **Behavioural Brain Research**. 2006 Jun 3; 170(1):110-8.
64. Contarino A and **Papaleo F**. The corticotropin-releasing factor receptor-1 pathway mediates the negative affective states of opiate withdrawal. **PNAS**. 2005 Dec 20; 102(51):18649-18654.

Book chapters:

1. Scheggia D, **Papaleo F**.
The Genetics of Cognition in Schizophrenia: Combining Mouse and Human Studies. In: Neuro-Phenome, Handbook of Neurobehavioral Genetics and Phenotyping. **Wiley Blackwell 2017**. Chapter 6, pages 115-132.
2. Managó F, Huang H, **Papaleo F**.
Modeling cognitive impairment. In: Modeling Psychopathological Dimensions of Schizophrenia: From Molecules to Behavior. Handbooks of Behavioral Neuroscience, volume 23. **Academic Press, Elsevier 2016**. Chapter 6, pages 69-84.
3. **Papaleo F**, Chen J, Weinberger DR.
Animal models of genetic effects on cognition. In: The Genetics of Cognitive Neuroscience. **MIT press. 2009**. Chapter 3, pages 51-94.

Patents and related outputs:

- Italian Patent, deposited the 10.05.2021 with n. 102021000011480: "Composizioni per l'uso nel trattamento della sindrome da delezione 22q11.2".
- **February 20th 2018**: Commercial agreement and exclusive know-how license with UGO Basile Srl for the "Two-chamber Operon ID/ED task apparatus".
- International Patent, deposited the 11.02.2016. n. WO 2016/020850: "A novel therapeutic indication of dopamine D2 receptor antagonists".
- Italian Patent, deposited the 06.08.2014 with n. TO2014A000637: "Nuova indicazione terapeutica di antagonisti e agonisti dei recettori D2 della dopamina".

EDITORIAL AND RELATED ACTIVITIES

Guest Editor for:

- CNS & Neurological Disorders-Drug Targets (CNSND-DT). Special issue: "Catechol-O-Methyltransferase as a drug target for nervous system disorders". 2012 May.

Editorial Board:

- CNS & Neurological Disorders-Drug Targets (CNSND-DT).
- Stress, Brain and Behavior.
- Frontiers in Behavioral Neuroscience.
- Frontiers in Pharmacology.
- Frontiers in Molecular Neuroscience.
- Frontiers in Psychiatry – Schizophrenia.

Ad Hoc Reviewer for journals:

- ACS Chemical Neuroscience.
- Behavioral Neuroscience.

- Behavioural Brain Research.
- Biological Psychiatry.
- Bio-protocol (Neuroscience).
- Bipolar disorders.
- Brain.
- Brain Behavior and Immunity.
- Brain Imaging and Behavior.
- Brain Research Bulletin.
- British Journal of Pharmacology.
- Cell Reports.
- Cerebral Cortex.
- CNS & Neurological Disorders-Drug Targets.
- Cognitive Neuropsychiatry.
- Current Biology.
- Developmental Neurobiology.
- eNeuro.
- European Archives of Psychiatry and Clinical Neuroscience.
- European Neuropsychopharmacology.
- European Journal of Neuroscience.
- Experimental Neurology.
- Expert Opinion On Drug Discovery.
- Frontiers (in Behavioral Neuroscience; in Human Neuroscience; in Pharmacology; in Psychiatry).
- Genes, Brain and Behavior.
- Human Molecular Genetics.
- iScience.
- Journal of Affective Disorders.
- Journal of Clinical Medicine.
- Journal of Neurochemistry.
- Journal of Neuroscience.
- Journal of Neuroscience Methods.
- Journal of Psychiatric Research.
- Learning & Memory.
- Molecular Autism.
- Molecular Brain.
- Molecular Neurobiology.
- Molecular Psychiatry.
- Nature Communications.
- Nature Protocols.
- Neurobiology of Disease.
- Neurochemistry International.
- NeuroImage.
- Neuron.
- Neuropharmacology.
- Neuropsychopharmacology.
- Neuroscience.
- Neuroscience Bulletin.
- Neuroscience & Biobehavioral Reviews.
- Neuroscience Letters.
- Pain.

- Pharmacology, Biochemistry and Behavior.
- Pharmacological Research.
- PLOS ONE.
- Progress in Neuro-Psychopharmacology & Biological Psychiatry.
- Psychological Medicine.
- Psychoneuroendocrinology.
- Psychopharmacology.
- Scientific Reports.
- Synapse.
- The International Journal of Neuropsychopharmacology.
- The Journal of Neuroscience.
- The Journal of Visualized Experiments (JoVE).
- Translational Psychiatry.

Ad Hoc Reviewer for grants:

- ERAPerMed, European Commission (2021- present).
- Dutch Research Council, The Netherlands (2020-present).
- China Israel Research Program, China & Israel (2020-present).
- German Research Foundation, Germany (2020-present).
- Fondation pour la Recherche Médicale, France (2020-present).
- Wellcome Trust, UK (2019-present).
- Israel Science Foundation (2019-present).
- MIUR (Ministero dell'Istruzione, dell'Università e della Ricerca), (2013-present).
- Marie Curie Grants, European Commission (2012-present).
- French National Research Agency (ANR), (2018- present).
- Regione autonoma Sardegna (2018-present).
- French National Research Agency (ANR). France Committee member (2015-2018).
- University of Pavia Blue Sky Research Grants (2017-2018).
- National Medical Research Council, Singapore (2011-2013).
- Project SEED Grants; Istituto Italiano di Tecnologia, Italy (2009-2011).

TEACHING

- 4-hour course “Mouse-Human Studies of Cognitive Processes”. Master in Neuroscience and Neurofunctional Techniques. University of Trieste, Italy (December 2019).
- 27 hours (9-hour/year) course on “Studying the developmental trajectories of higher order cognitive functions and the impact of genetic variations in mice”. For PhD students in Neuroscience and Brain Technologies. Istituto Italiano di Tecnologia, Genova, Italy (October 2015; November 2016; November 2017).
- 4-hour course, Corso Residenziale di Alta Specializzazione per Professionisti della Salute Mentale in Età Evolutiva. Ospedale Bambino Gesù, Roma, Italy (June 2014).
- 3-hour course on “Preclinical Studies of Cognitive Functions”. For Biotechnology students. University of Padova, Padova, Italy (November 2013).
- 40-hour course on “Pharmacology”. For nurses and nursing students at the Medical School of the University of Padova, Rovigo, Italy. (September 2013-January 2014).

- 3-hour course on “Genetics of Schizophrenia: Modeling Madness in Mice”. University of Catania, Italy. (May 2013).
- 40-hour course on “Pharmacology”. For nurses and nursing students at the Medical School of the University of Padova, Treviso, Italy. (September 2012-January 2013).
- 9-hour course on “Studying cognition in mice”. For PhD students in Neuroscience and Brain Technologies XXVII cycle. Istituto Italiano di Tecnologia, Genova, Italy (July 2012).
- 9-hour course on “Studying cognition in mice”. For PhD students in Neuroscience and Brain Technologies XXVI cycle. Istituto Italiano di Tecnologia, Genova, Italy (September 2011).
- 9-hour course on “Studying cognition in mice”. For PhD students in Neuroscience and Brain Technologies XXV cycle. Istituto Italiano di Tecnologia, Genova, Italy (September 2010).
- 3-hour course on “Role of corticotropin releasing factor receptor 1 in opiate withdrawal”. For resident medical students in Pharmacology, University of Padova, Italy (November 2004).

INVITED LECTURES

- Circuits of Emotion Discrimination. Barcelona Biomedical Research Park, Spain (June 2021).
- Circuits of Emotion Discrimination. Instituto de Neurociencias Alicante, Spain (May 2021).
- Neurobiology of Emotion Discrimination. University of Haifa. Israel, Virtual (March 2021).
- Perinatal Antiinflammatory Oxytocin Effects Ameliorates Developmental Trajectories in 22q11.2 Deletion Syndrome. Center for Neuroscience and Cognitive Systems. Rovereto. Italy, Virtual (March 2021).
- Mouse-Human Studies of Cognitive Control and Social Cognition. University of Verona. Italy, Virtual (September 2020).
- Mouse-Human Studies of Cognitive Control. FENS 2020 Virtual Forum (July 2020).
- Perinatal Antiinflammatory Oxytocin Effects Ameliorates Developmental Trajectories in 22q11.2 Deletion Syndrome. Swiss Institute of Allergy and Asthma Research (SIAF). University of Zurich. Switzerland, Virtual (June 2020).
- Mouse-Human Studies of Cognitive Control and Social Cognition. The Synapsy Conference on the Neurobiology of Mental Health. Geneva, Switzerland (February 2020).
- Circuits of Emotion Discrimination. NeuroCentre Magendie, Bordeaux Neurocampus. Bordeaux, France (January 2020).
- A Precision Medicine Genetic Marker for Core Cognitive Deficits in Schizophrenia. University of Erlangen-Nuremberg. Germany (December 2019).
- Neural Circuits of Emotion Discrimination. University of Trieste. Italy (December 2019).
- Genetic Modulators of Cognitive Responses to Antipsychotic Drugs. Italian Society of Pharmacology. Firenze, Italy (November 2019).
- Perinatal Antiinflammatory Oxytocin Effects Ameliorates Developmental Trajectories in 22q11.2 Deletion Syndrome. Cardiff University. Cardiff, UK (October 2019).
- Oxytocin signaling in the central amygdala modulates emotion discrimination in mice. ESN, European Society for Neurochemistry biennial meeting. Milano, Italy (September 2019).

- Perinatal Antinflammatory Oxytocin Effects Ameliorates Developmental Trajectories in 22q11.2 Deletion Syndrome. IBNS, International Behavioral Neuroscience Society Annual Meeting. Cairns, Australia (June 2019).
- Perinatal Antinflammatory Oxytocin Effects Ameliorates Developmental Trajectories in 22q11.2 Deletion Syndrome. NeuRa, University of New South Wales. Sydney, Australia (June 2019).
- Neural Circuits of Emotion Discrimination. Neural Circuits of Social Cognition. Neuroscience School of Advanced Studies. Venice, Italy (June 2019).
- Reading Emotions Through Oxytocin. 13th World Congress on Neurohypophysial Hormones. Ein Gedi, Dead Sea, Israel (April 2019).
- Perinatal Antinflammatory Oxytocin Effects Ameliorates Developmental Trajectories in 22q11.2 Deletion Syndrome. Paris Descartes University, Institute of Psychiatry and Neuroscience of Paris, France (March 2019).
- Mouse-Human Studies for Executive Cognitive Functions. Workshop on cognitive and behavioral screening of rodents. Brno, Czech Republic (March 2019).
- Somatostatin Interneurons in the Prefrontal Cortex Control Emotion Recognition in Mice. Annual Winter Conference on Brain Research. Snowmass, CO, USA (January 2019).
- Precision Medicine, in Neurodevelopmental and Psychiatric Disorders. University of Basel, Switzerland (January 2019).
- Mouse-Human Studies of Cognitive and Social Processes. Institute for Neuropathology, University of Zurich, Switzerland (January 2019).
- Perinatal Oxytocin Rescues Developmental Trajectories in a Mouse Model of 22q11.2 Microdeletion Modulating the Immune System. Workshop, More than Neurons: toward a less neuronocentric view of brain disorders. Torino, Italy (November 2018).
- Genetic markers for personalized medicine in schizophrenia. Neuroscienze e Psichiatria. University of Milano, Italy (November 2018).
- Bottom-Up and Top-Down Control of Emotion Recognition. F. Hoffmann-La Roche AG, Basel, Switzerland (October 2018).
- Developmental Trajectories of Schizophrenia-Relevant Abnormalities in a Mouse Model of 22q11.2 Deletion Syndrome. Training school/hands-on workshop in “Convergence Neuroscience: bridging the gap between human patients and animal models of neurodevelopmental disorders”. Istituto Italiano di Tecnologia, Genova, Italy. (October 2018).
- Reading emotions through oxytocin. Neurobiology of empathy conference. Nencki Institute. Warsaw, Poland (September 2018).
- Oxytocin-Dependent Emotion Recognition in Mice. International workshop on “Understanding the neuroregulatory actions of oxytocin and its potential clinical applications”. Erice, Italy (May 2018).
- Emotion Recognition Abilities Rely on Somatostatin Interneurons Activity in Mouse Prefrontal Cortex. IIT, Lecce, Italy (May 2018).
- The dysbindin-1A isoform modulates basal ganglia-related phenotypes through astrocytic-dependent functioning. International Astrocytes School. Bertinoro, Italy (April 2018).

- Frontal Cortex Development and Risk for Psychopathology: Molecular and Genetic Mediators as Possible Biomarkers? Symposium Chair. SIRS Biennial Schizophrenia International Research Society Conference. Florence, Italy (April 2018).
- Developmental Trajectories of Schizophrenia-Relevant Abnormalities in a Mouse Model of 22q11.2 Deletion Syndrome. SIRS Biennial Schizophrenia International Research Society Conference. Florence, Italy (April 2018).
- Convergent Neuroscience, Cognitive and Social Processes. MINDDS (Maximising Research Impact in Neurodevelopmental Disorders), Belgrade, Serbia (March 2018).
- A Genetic Mechanism for Cognitive Response to Antipsychotic Drug Treatment. Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy (February 2018).
- Cannabis and animal models of psychosis. SOPSI 2018, Roma, Italy (February 2018).
- Reading emotions through oxytocin. Workshop on Neuromodulation. University La Sapienza. Roma, Italy (February 2018).
- Reading emotions through oxytocin. International meeting of the integrated brain and behavior research center. University of Haifa. Israel (January 2018).
- Impact of the 22q11.2 microdeletion on adolescent brain development. ACNP, American College of Neuropsychopharmacology, Annual Meeting, Palm Spring, CA, USA (December 2017).
- Oxytocin-Dependent Emotion Recognition in Mice. University of Padova, Italy (November 2017).
- Dysbindin-1 genetics through cortical D2 trafficking differentiate subjects with better cognitive responses to antipsychotic drugs. Society for Neuroscience 2017, Annual Meeting, Washington, DC, USA (November 2017).
- A precision medicine genetic marker for core cognitive deficits in schizophrenia. SIF, Societa' Italiana di Farmacologia, annual conference. Rimini, Italy (October 2017).
- Animal model of human brain diseases. Scientific Director with Dr. Carsten Wotjak. Faculty speakers: Francesco Papaleo, Carsten Wotjak, Anna Beyeler, Marta Moita, David Belin, Trevor Robbins, Vivien Chevalyere, Ofer Yizhar, Jens Bruning, Alon Chen, Michal Schwartz. International Summer School of Neuroscience. Noto, Italy (July 2017).
- Dysbindin-1 genetics modulate cognitive responses to antipsychotics through D2-related mechanisms within the prefrontal cortex. IBNS, International Behavioral Neuroscience Society Annual Meeting. Hiroshima, Japan (June 2017).
- Genetics of Cognitive and Social Processes in Health and Psychiatric Disorders. Boehringer Ingelheim Pharma GmbH & Co. Biberach/Riss, Germany (April 2017).
- Dysbindin-1 genetics as a precision medicine marker for core cognitive deficits in schizophrenia. University of Oxford. UK (February 2017).
- Developmental Trajectories of Schizophrenia-Relevant Abnormalities in a Mouse Model of 22q11.2 Deletion Syndrome. Seminaire des Neurosciences. University of Genève. Switzerland (January 2017).
- Genetic driven D2-D3 imbalance in the prefrontal cortex as the base for pro-cognitive treatments in schizophrenia. 2016-2017 European Frontiers in Biomedical and Biotechnological Sciences series. Catania, Italy (November 2016).

- Arc/Arg3.1 genetic disruption in mice causes dopamine system alterations and neurobehavioral phenotypes related to schizophrenia. International Behavioral Neuroscience Society 25th Annual Meeting. Budapest, Hungary (June 2016).
- A precision medicine genetic marker for core cognitive deficits in schizophrenia. International Behavioral Neuroscience Society 25th Annual Meeting. Budapest, Hungary (June 2016).
- A precision medicine genetic marker for core cognitive deficits in schizophrenia. School on Neuropsychopharmacology. Drug Discovery in Schizophrenia. Catania, Italy (March 2016).
- Genetics of cognition in health and psychiatric disorders. F. Hoffmann-La Roche AG, Basel, Switzerland (February 2016).
- COMT-Cannabinoids interaction as a risk factor in developing schizophrenia. SOPSI 2016, Milano, Italy (February 2016).
- A precision medicine genetic marker for core cognitive deficits in schizophrenia. University of Padova, Padova, Italy (February 2016).
- COMT-Cannabinoids interaction as a risk factor in developing schizophrenia. Clinica Psichiatrica – Policlinico, Università degli Studi di Milano, Italy (October 2015).
- COMT modulation of long-term memory through dysregulation of the endocannabinoid System. 7th European Workshop on Cannabinoid Research and IACM 8th Conference on Cannabinoids in Medicine. Sestri Levante, Italy (September 2015).
- Genetics of cognition: relevance to schizophrenia. Summer school, international PhD Program in Neuroscience. Catania, Italy (July 2015).
- Arc/Arg3.1 genetic disruption produces schizophrenia-like phenotypes in mice converging on frontal-hippocampal-striatal dopamine system alterations. 2015 Spring Hippocampal Research Conference. Taormina, Italy (June 2015).
- COMT*Dysbindin-1 concomitant reduction produce schizophrenia-like phenotypes converging on dopamine pathways. Weizmann Institute of Science. Rehovot, Israel (March 2015).
- Studying cognitive development and schizophrenia-like phenotypes in genetically modified mice relevant to 22q11DS. University of Geneva School of Medicine. Geneva, Switzerland (February 2015).
- Chair and organizer of the Symposium “Genetic and environmental modulation of prefrontal cortex pathways in health and disease: from rodents to humans”. 48th Annual Winter Conference on Brain Research. Big Sky, MT, USA. (January 2015).
- Mouse models of genetic effects on cognition: role of dopamine pathways. International PhD Program in Neuroscience. Catania, Italy (July 2014).
- Studying cognitive development and schizophrenia-like phenotypes in genetically modified mice relevant to 22q11DS. 9th Biennial International 22q11.2 Deletion Syndrome Conference. Palma de Mallorca, Spain (June 2014).
- Dysbindin-1 and the dopaminergic system: relevance to schizophrenia and its treatment. University of Padova, Padova, Italy (March 2014).
- Genetics of Schizophrenia and Cognition: from Mice to Humans. Istituto Scientifico San Raffaele, Milano, Italy (March 2014).

- Genetics of higher-order cognitive functions, in health and disease. IIT workshop for Scientific Plan, Genova, Italy (March 2014).
- Translational studies in mice to unravel the genetics of higher order cognitive functions. CSNII school on neurotechniques 2014. Università' di Padova, Italy (March 2014).
- Genetics of Schizophrenia and Cognition. Institut Francois Magendie, Bordeaux, France (December 2013).
- Dysbindin-1 modulates cognitive deficits relevant to schizophrenia via dopamine pathways. Dopamine 2013. Alghero, Italy. (May 2013).
- Genetics of Schizophrenia: Modeling Madness in Mice. Incontro sulla Schizofrenia. University of Padova, Italy. (March 2013).
- Arc genetic disruption produces schizophrenia-like phenotypes in mice. 46th Annual Winter Conference on Brain Research. Breckenridge, CO, USA. (January 2013).
- Executive Functions and Social Behavior in Mice: Relevance to Schizophrenia. Università' di Milano-Bicocca and A.O. San Gerardo. Milano and Monza, Italy (September 2012).
- Lectio Magistralis. COMT, Dysbindin and their interaction: implications for schizophrenia. Università' degli Studi di Verona. Verona, Italy (August 2012).
- Chair and organizer of the Symposium "Modeling schizophrenia symptoms and neurobiology in mice". IBNS 21st Annual Meeting. Kailua-Kona, Hawaii, USA (June 2012).
- Development of cognitive deficits relevant to schizophrenia in COMT and Dysbindin mouse mutants. IBNS 21st Annual Meeting. Kailua-Kona, Hawaii, USA (June 2012).
- Schizophrenia: from basic research to clinical management. Animal models: genetic variations. University of Insubria. Busto Arsizio, Italy (February 2012).
- COMT, Dysbindin and their interaction: towards early detection and personalized interventions for schizophrenia-related cognitive deficits. F. Hoffmann-La Roche AG, Basel Switzerland (November 2011).
- Development of cognitive deficits relevant to schizophrenia in COMT and Dysbindin mouse mutants. Center for Neurosensory Disorders. UNC School of Dentistry; Chapel Hill, NC, USA (November 2011).
- Selecting Promising Animal Paradigms. Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS). Washington, DC, USA (April 2011).
- Geni, ambiente e psicosi: dai modelli animali all'uomo. Società Italiana di Psicopatologia. PSICHIATRIA 2011: Vulnerabilità, esordi, intervento precoce. Roma, Italy (February 2011).
- COMT, dysbindin and their interaction: implications for schizophrenia. Séminaires de Neurobiologie, Institut des Neurosciences de Bordeaux, Bordeaux, France (September 2009).
- Disease models of genetic susceptibility for complex brain disorders. 42nd Annual Winter Conference on Brain Research, Colorado, USA (January 2009).
- COMT and Dysbindin: insights from genetic mouse models. Genes, Cognition and Psychosis Program/NIMH/NIH Seminar (October 2008).
- COMT and Dysbindin: insights from genetic mouse models. Italian Institute of Technology, IIT, Genova, Italy (October 2008).
- COMT and Dysbindin: insights from genetic mouse models. Istituto Superiore di Sanita', ISS, Roma, Italy (October 2008).

- COMT, Dysbindin and their interaction: insights from genetic mouse models. Clinical Brain Disorders Branch/NIMH/NIH (April 2008).
- Genetic dissection of the role of Catechol-O-Methyltransferase (COMT) in cognition and stress reactivity in mice. Italian Institute of Technology, IIT, Genova, Italy (April 2008).
- Genetic manipulation of Catechol-o-Methyltransferase (COMT) in mice affects specific cognitive processes. NIMH 11th Annual Scientific Retreat (September 2007).

POSTER PRESENTATIONS

1. Scarsi F, Guadagna S, Dautan D, Mastrogiacomo R, Scheggia D, Nigro M, Ballard T, Olcese U, **Papaleo F** (2019). Cortical Encoding of Attentional Set-Shifting Abilities. Society for Neuroscience 2019, Annual Meeting, Chicago, IL, USA.
2. Contarini G, Maltese F, Ferretti V, **Papaleo F** (2019). Interaction between endocannabinoid and oxytocin system: implication for social behavior. Society for Neuroscience 2019, Annual Meeting, Chicago, IL, USA.
3. Scheggia D, Managò F, Maltese F, Bruni S, Nigro M, Dautan D, Latuske P, Contarini G, Gomez-Gonzalo M, Reque LM, Ferretti V, Castellani G, Mauro D, Bonavia A, Carmignoto G, Yizhar O, **Papaleo F** (2019). Somatostatin interneurons in the prefrontal cortex control affective state discrimination in mice. The Assembly and Function of Neuronal Circuits. Ascona, Switzerland.
4. Scheggia D, Managò F, Maltese F, Bonavia A, Nigro M, Bruni S, Ferretti V, Huang H, Yizhar O, **Papaleo F** (2018). Emotion recognition abilities rely on somatostatin interneurons activity in mouse prefrontal cortex. Gordon Research Conferences: Optogenetic Approaches to Understanding Neural Circuits and Behavior. Grand Summit Hotel at Sunday River, ME, USA. **Best poster award.**
5. Castellani G., Ciampoli M, Albanesi E, De Martin S, **Papaleo F** (2018). Perinatal intranasal oxytocin rescues aberrant developmental trajectories in a mouse model of 22q11.2 microdeletion modulating the blood-cerebrospinal fluid-barrier permeability. FENS Forum of Neuroscience, Berlin, Germany.
6. Scarsi F, Guadagna S, Mastrogiacomo R, Scheggia D, Ballard T, Olcese U, **Papaleo F** (2018). Cortical Encoding of Attentional Set-Shifting Abilities. FENS Forum of Neuroscience, Berlin, Germany.
7. Contarini G, Maltese F, Nigro M, Ferretti V, **Papaleo F** (2018). Cannabinoid involvement in the development of social deficits. FENS Forum of Neuroscience, Berlin, Germany.
8. Nigro M, Ferretti V, Bruni S, Huang H, Contarini G, Losi G, Basilico B, Lia A, Ragozzino D, Carmignoto G, **Papaleo F** (2018). Oxytocin modulates prefrontal cortex activity during social exploration. FENS Forum of Neuroscience, Berlin, Germany.
9. Ferretti V, Bonavia A, Maltese F, Huang H, Gigliucci V, Nigro M, Scheggia D, Managò F, Chini B, Grinevich V, **Papaleo F** (2018). Reading emotions through oxytocin. FENS Forum of Neuroscience, Berlin, Germany. **Poster award.**
10. Managò F, Scheggia D, Maltese F, Bonavia A, Nigro M, Bruni S, Ferretti V, Huang H, Yizhar O, **Papaleo F** (2018). Emotion recognition abilities rely on somatostatin interneurons activity in mouse prefrontal cortex. FENS Forum of Neuroscience, Berlin, Germany.

11. Nigro M, Bruni S, Ferretti V, **Papaleo F** (2017). Oxytocin effects on social behavior are genetically modulated by cortical functioning. Society for Neuroscience 2017, Annual Meeting, Washington, DC, USA.
12. Contarini G, Scheggia D, Zamberletti E, Mereu M, Ferretti V, Managò F, **Papaleo F** (2017). Remote memories are enhanced by COMT activity through the dysregulation of the cannabinoid system in the prefrontal cortex. Society for Neuroscience 2017, Annual Meeting, Washington, DC, USA.
13. Mastrogiacomo R, Mauro D, Ferretti V, Waddington JL, Weickert CS, **Papaleo F** (2017). The Dysbindin-1A isoform selectively modulates basal ganglia-related phenotypes through astrocytic-dependent functioning. Society for Neuroscience 2017, Annual Meeting, Washington, DC, USA.
14. Ferretti V, Bonavia A, Huang H, Maltese F, Nigro M, Gigliucci V, Scheggia D, Managò F, Chini B, Grinevich V, **Papaleo F** (2017). Oxytocin-Dependent Emotion Recognition in Mice. Gordon Research Conferences: Amygdala Function in Emotion, Cognition and Disease. Stonehill College, Easton, USA.
15. Mastrogiacomo R, Monari S, Orso G, **Papaleo F** (2016). Dysbindin-1A Isoform reduction leads to striatal-dependent behavioral and molecular phenotypes relevant for schizophrenia. The brain conferences 2016 “New Insights into Psychiatric Disorders”. Copenhagen, Denmark. **Poster award.**
16. Guadagna S, Huang H, Scheggia D, Borrelli E, Ballard T, **Papaleo F** (2016). Behavioral deficits and related in vivo electrophysiological recordings in a mouse model of schizophrenia with genetic reduction of dysbindin-1 and D2L. Dopamine 2016. Vienna, Austria.
17. Ferretti V, Huang H, Gentili G, Nigro M, Busnelli M, Chini B and **Papaleo F** (2016). Loss of the schizophrenia susceptibility gene dysbindin-1 affects mice sociability and oxytocin brain pathways. Synapsy conference. Geneva, Switzerland.
18. Ciampoli M, **Papaleo F** (2016). Developmental trajectories of schizophrenia-relevant behavioral abnormalities in a mouse model of 22q11.2 Deletion Syndrome. 10th International 22q11.2 Conference. Sirmione, Italy.
19. Huang H, Michetti C, Gigliucci V, Busnelli M, Gentili G, Giancardo L, Hilario C, Sona D, Murino V, Chini B, Scattoni ML, **Papaleo F** (2016). Social Deficits in Dysbindin-1 Knockout Mice Are Ameliorated by Intranasal Oxytocin. FENS Forum of Neuroscience 2016. Copenhagen, Denmark.
20. Contarini G, Mereu M, **Papaleo F** (2016). COMT-Cannabis interaction in adolescence as a risk factor in developing schizophrenia. School on Neurotechniques. Noto, Italy.
21. Contarini G, Mereu M, Buonaguro E, Brunoro R, Managò F, Iasevoli F, DeBartolomeis A, **Papaleo F** (2016). Genetic-driven partial reduction of the dopamine transporter (DAT) in mice produces ADHD- but not schizophrenia-relevant phenotypes, Dopamine 2016. Vienna, Austria.
22. Huang H., Michetti C., Gigliucci V., Buselli M., Gentili G., Giancardo L., Hilario C., Sona D., Murino V., Chini B., Scattoni M.L., **Papaleo F** (2015). Social Deficits in Dysbindin-1 Knockout Mice Are Ameliorated by Intranasal Oxytocin. 11th World Congress on Neurohypophysial Hormones (WCNH). Queenstown, New Zealand.
23. Ferretti V., Nigro M., Huang H., Gentili G., **Papaleo F** (2015). Loss of the schizophrenia susceptibility gene dysbindin-1 affects mice sociability and social memory. 4th Champalimaud Neuroscience Symposium. Portugal.
24. Guadagna S., Huang H., Borrelli E., Ballard T., **Papaleo F** (2015). Concomitant Genetic Reduction of Dysbindin-1 and D2L is Associated with Cognitive and Schizophrenia-Like Deficits. EBBS/EBPS meeting. Verona, Italy.

25. Guadagna S., Huang H., Scheggia D., Borrelli E., Ballard T., **Papaleo F** (2015). Schizophrenia-like deficits and related in vivo electrophysiological readouts following genetic reduction of dysbindin-1 and D2L. RPF symposium Copenhagen, Denmark.
26. Brunoro R, Mereu M, **Papaleo F** (2014). Effects of COMT genetic reduction in an implemented 5-choice serial reaction time task in mice. Società Italiana di Farmacologia, Rimini, Italy.
27. Gentili G, Huang H, **Papaleo F** (2014). Intranasal oxytocin ameliorates social deficits in the schizophrenia-relevant dysbindin-1 knockout mice. Società italiana di Farmacologia, Rimini, Italy.
28. Mereu M, Contarini G, Brunoro R, Gainetdinov R, **Papaleo F** (2014). Genetic-driven partial reduction of the dopamine transporter (DAT) in mice produces ADHD but not schizophrenia-relevant behavioral phenotypes. Society for Neuroscience 2014, Annual Meeting, Washington, DC, USA.
29. Guadagna S, Huang H, Borrelli E, Ballard T, **Papaleo F** (2014). D2L/S and dysbindin genetic interaction modulates behavioral phenotypes relevant to schizophrenia. Society for Neuroscience 2014, Annual Meeting, Washington, DC, USA.
30. Guadagna S, Huang H, Borrelli E, Ballard T, **Papaleo F** (2014). The genetic interaction between D2L/S and dysbindin modulates behavioral phenotypes relevant to schizophrenia. The 5th Roche Postdoc Fellowship (RPF) Symposium, Munich, Germany.
31. Managò F, Sannino S, Gainetdinov R, Wang K, **Papaleo F** (2013). Arc involvement in Schizophrenia-related symptoms in mice. Dopamine 2013, Alghero, Italy.
32. Huang H, Michetti C, Busnelli M, Giancardo L, Managò F, Sannino S, Scheggia D, Sona D, Murino V, Chini B, Scattoni ML, **Papaleo F** (2013). Intranasal Oxytocin effects in mice. Dopamine 2013, Alghero, Italy.
33. Mereu M, Scheggia D, **Papaleo F** (2013). Catechol-O-methyltransferase (COMT) modulates long-term memory in mice. Dopamine 2013, Alghero, Italy.
34. Sannino S, Gozzi A, Cerasa A, Scheggia D, Managò F, De Pietri Tonelli D, Bifone A, Spalletta G, Weinberger DR, **Papaleo F** (2013). Sex-specific effect of COMT on cortical anatomy. Dopamine 2013, Alghero, Italy.
35. Scheggia D, Kochlamazashvili G, Dityatev A, **Papaleo F** (2013). Dysbindin-1 genetic disruption modulates cognitive flexibility in mice. Dopamine 2013, Alghero, Italy.
36. Carr GV, Bebensee A, Tian Q, Chen J, **Papaleo F**, Weinberger DR (2012). KCNH2-3.1 transgenic mice exhibit deficits in object location memory. Society for Neuroscience 2012, Annual Meeting, New Orleans, USA.
37. Xun R, Carr GV, Tian Q, Sibley DR, Chen J, Weinberger DR, **Papaleo F** (2012). Working memory and recency memory in Dopamine D5 receptor knockout mice. Society for Neuroscience 2012, Annual Meeting, New Orleans, USA.
38. Scheggia D, **Papaleo F** (2012). A new task to study executive control in mice. IBNS 21st Annual Meeting. Kailua-Kona, Hawaii, USA
39. Scheggia D, Weinberger DR, **Papaleo F** (2012). A novel semi-automated Attentional Set Shifting Task for mice. 3rd Biennial Schizophrenia International Research Society Conference. Florence, Italy.
40. **Papaleo F**, Burdick MC, Callicott JH, Weinberger DR (2012). Epistatic interaction of COMT and DTNBP1 modulates working memory performance in mice and related prefrontal physiology in humans. 3rd Biennial Schizophrenia International Research Society Conference. Florence, Italy.
41. Scheggia D, Bebensee A, Benfenati F, Weinberger DR, **Papaleo F** (2011). Toward the automatization of the Attentional Set Shifting Task in mice. Society for Neuroscience 2011, Annual Meeting, Washington, DC, USA.

42. Carr GV, Sibley DR, Weinberger DR, **Papaleo F** (2011). Dopamine D5 receptor knockout mice display prefrontal cortex-dependent cognitive deficits. Society for Neuroscience 2011, Annual Meeting, Washington, DC, USA.
43. Bebensee A, Carr GV, Aney J, Chen J, **Papaleo F**, Weinberger DR (2011). Cognitive functions in KCNH2-3.1 transgenic mice. Society for Neuroscience 2011, Annual Meeting, Washington, DC, USA.
44. Burdick MC, Straub RE, **Papaleo F**, Kolachana B, Zhang F, Mattay VS, Weinberger DR, Callicott JH (2011). Genetic Interaction between COMT and Dysbindin Effects Prefrontal Cortex Function During a BOLD fMRI Working Memory Paradigm. Society of Biological Psychiatry, 66th Annual Meeting, San Francisco, CA, USA.
45. Huppe-Gourgues F, **Papaleo F**, Jingshan C, Weinberger DR, O'Donnell P (2010). Downregulation of D1 modulation of cell excitability in prefrontal pyramidal neurons in slices from val/val COMT mice. Society for Neuroscience 2010, San Diego, CA, USA.
46. Scheggia D, Garcia S, Benfenati F, Weinberger DR, **Papaleo F** (2010). Increased long-term memory functions in COMT Val-transgenic mice. 7th FENS forum of European Neuroscience. Amsterdam, The Netherlands.
47. **Papaleo F**, Jenkins KA, Weinberger DR, Law AJ (2010). Impaired Temporal Order Recognition Memory in Neuregulin 1 Type IV Transgenic Mice. International Behavioral Neuroscience Society 19th Annual Meeting, Villisimius, Sardinia, Italy.
48. **Papaleo F**, Chen J, Lu B, Crawley JN, Weinberger DR (2010). Genetic interaction between COMT and Dysbindin produce schizophrenia-like phenotypes. Società Italiana di Psicopatologia. PSICHIATRIA 2010: No Health Without Mental Health. Roma, Italy.
49. Wang Y, **Papaleo F**, Jenkins KA, Weinberger DR, Law AJ (2009). Transgenic over expression of Neuregulin 1, type IV regulates synaptic maturation in-vitro and impairs cortical function in mice. American College of Neuropsychopharmacology, 48th Annual Meeting, Hollywood, FL. USA.
50. **Papaleo F**, Chen J, Lu B, Crawley JN, Weinberger DR (2009). Genetic interaction between COMT and Dysbindin produce schizophrenia-like phenotypes. Neuroscience 2009, Annual Meeting, Chicago, IL, USA.
51. Garcia SJ, **Papaleo F**, Erickson L, Tian Q, Chen J, Crawley JN, Weinberger DR (2009). Working memory deficits in Catechol-O-Methyltransferase knockout female mice: opposite phenotype compared to male mice. Neuroscience 2009, Chicago, IL, USA.
52. Jenkins KA, **Papaleo F**, Chen J, Crawley JN, Weinberger DR, Law AJ (2009). Impaired Temporal Order Recognition Memory in Neuregulin 1 Type IV Transgenic Mice. NIMH 13th Annual Scientific Retreat, Gettysburg, PA, USA.
53. **Papaleo F**, Crawley JN, Chen J, Lu B, Weinberger DR (2008). Faster acquisition but not better performance of working memory, and increased startle, in dysbindin knockout mice. 47th American College of Neuropsychopharmacology Meeting, Scottsdale, AZ, USA.
54. **Papaleo F**, Crawley JN, Chen J, Lu B, Weinberger DR (2008). Improved working memory but increased stress responses in dysbindin knockout mice. NIMH 12th Annual Scientific Retreat, Gettysburg, PA, USA.
55. **Papaleo F**, Crawley JN, Lipska BK, Weinberger DR, Chen J (2008). Genetic dissection of the role of Catechol-O-Methyltransferase (COMT) in stress reactivity in mice. International Behavioral Neuroscience Society, St. Thomas - US Virgin Islands.
56. **Papaleo F**, Crawley JN, Lipska BK, Song J, Liu G, Pickel J, Weinberger DR, Chen J (2007). Evidence of evolutionary trade-off of cognitive and affective functions: from *in vitro* mutagenesis analyses on COMT genes and behavioral analyses on transgenic mice carrying human COMT transgene. American College of Neuropsychopharmacology, 46th Annual meeting, Boca Raton, FL, USA

57. **Papaleo F**, Crawley JN, Weinberger DR, Chen J (2007). Genetic manipulation of Catechol-o-Methyltransferase (COMT) in mice affects specific cognitive processes. Neuroscience 2007, Annual Meeting, San Diego, CA, USA.
58. **Papaleo F**, Tabarin AC, Kieffer BL, Contarino A (2007). The μ -opioid receptor mediates the motivational properties of food intake. Neuroscience 2007, San Diego, USA.
59. Contarino A, Ghozland S, Ingallinesi M, Roberts AJ, Koob GF, **Papaleo F** (2007). Decreased somatic opiate withdrawal in CRF₂ receptor-deficient mice. Neuroscience 2007, Annual Meeting, San Diego, CA, USA.
60. Song J, Ye T, **Papaleo F**, Elkahloun A, Chen J, Lipska BK, Weinberger DR (2007). Gene Expression Profiles in Prefrontal Cortex of Catechol-o-methyltransferase (COMT) Knockout Mice. NIMH 11th Annual Scientific Retreat, Gettysburg, PA, USA.
61. Patnaik P, **Papaleo F**, Crawley JN, Weinberger DR, Chen J (2007). Investigating the Role of Catechol-o-Methyltransferase in Cognition and Psychosis through Transgenic Mice. American Academy of Neurology, 59th Annual Meeting, Boston, MA, USA.
62. Contarino A, **Papaleo F**, Kitchener P, Vale W, Piazza PV (2004). Absence of reward and sensitization induced by high cocaine doses in CRF₁ receptor-deficient mice. Neuroscience 2004, 34th Annual Meeting, San Diego, CA, USA.
63. **Papaleo F**, Ferrante D, Contarino A (2003). Spontaneous somatic morphine withdrawal: a gender, drug dose and time-course study in C57BL/6J mice. 10th Biennial EBPS Meeting, Antwerp, Belgium.
64. **Papaleo F**, Giusti P, Contarino A (2002). Valutazione della componente psichica della sindrome d'astinenza spontanea da morfina: studi sul topo. Società Italiana di Farmacologia. Aspetti Neurochimici e Farmacologici delle Dipendenze. Capri, Italy.
65. **Papaleo F**, Contarino A (2002). Motivational Indices of Spontaneous Opiate Withdrawal in Mice. VI Seminario nazionale per dottorandi in Farmacologia. Siena, Italy.

OTHER OUTREACH ACTIVITIES

- Disturbi Cognitivi: verso terapie *ad personam*. Venerdì della cultura al CREAMCAFE. Genova, March 2019.
- Seminar “*Marcatore genetici per la medicina personalizzata nelle psicosi e nelle schizofrenie*” for psychiatrists, medical doctors, nurses, patients’ and families’ associations. Organized by Kaleidos & iSPS Lombardia. Bergamo, June 2018.
- Workshop on precision medicine in psychiatry, television and journalists interviews, Scicli. June 2018.
- Caffè Scientifici, Pasticceria Liquoreria Marescotti di Cavo, Genova. December 2015.
- Interview at Community – RAI World. November 2015.
- Pint of Science. Pub Les Rouge, Genova, Italy. May 2015.
- WCBR outreach program at the Bozeman high school, USA. January 2015.
- Lessons for undergraduate students, Genova and Padova. 2014-2016.
- Radio Babboleo phone interview. May 2011.